PAT-SM6

PAT-SM6 is a natural human IgM monoclonal antibody that targets the 78-kDa glucose-regulated protein (GRP78, also known as BiP or HSPA5), which is abnormally expressed on the surface of cancer cells. It has demonstrated proapoptotic and antineoplastic activities by binding to GRP78 and inducing programmed cell death in tumor cells. Additionally, PAT-SM6 can bind oxidized low-density lipoprotein (oxLDL) and very low-density lipoprotein (VLDL), facilitating their import into cancer cells via GRP78, leading to intracellular lipid accumulation and apoptosis. The drug has shown strong preclinical activity against multiple myeloma, including synergy with proteasome inhibitors such as bortezomib. Clinical trials have indicated safety and preliminary efficacy in relapsed or refractory multiple myeloma patients. PAT-SM6 has been granted orphan drug status for multiple myeloma in both Europe and the USA[1][3][4][5][7][8].

Other names

anti-GRP78 monoclonal antibodyanti-GRP-78 monoclonal antibodyanti-GRP 78 monoclonal antibody